Soligenix, Inc. (SNGX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Soligenix, Inc. (SNGX) closed at USD 0.34 on 2026-10-14, a change of -78.2 % over the past year, with a market capitalization of USD 7.73M.

Soligenix, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Soligenix, Inc. key figures

Previous close

USD 0.34 (2026-10-14)

1-year change

-78.2 %

Market cap

USD 7.73M

Enterprise value

USD -1.78M

P/E ratio (trailing)

-0.43

P/E ratio (forward)

-1.42

EPS (trailing)

-0.83

EPS (forward)

-0.25

PEG ratio

n/a

Price to book

1.16

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.71

Employees

13

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Soligenix, Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Soligenix, Inc. and compare it with other stocks.